microRNA-223 mimic

microRNA-223 mimic is a **synthetic oligonucleotide RNA therapy** designed to restore or increase intracellular levels of the endogenous microRNA miR-223. Rather than being a uniquely identified branded or code-named drug, this term generally refers to research-use miR-223 replacement constructs used across preclinical studies to modulate gene-expression networks controlled by miR-223. Its intended pharmacology is sequence-based post-transcriptional repression of miR-223 target mRNAs through the RNA-induced silencing complex, with reported investigation in cancer and inflammatory biology, including studies of cholesterol homeostasis and tamoxifen resistance in breast cancer. Based on the provided evidence, this appears to be a non-specific therapeutic concept rather than a single clearly defined clinical asset from a named developer.

Other names

miRNA-223 mimicmiRNA223 mimicmiRNA 223 mimicmiR-223 mimicmiR223 mimicmiR 223 mimicmicroRNA-223 mimicmicroRNA223 mimicmicroRNA 223 mimic